Item Type | Name |
Academic Article
|
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
|
Academic Article
|
Editorial comment.
|
Academic Article
|
Finishing the picture: problems with public reporting of clinical trials.
|
Concept
|
Antineoplastic Agents
|
Concept
|
Antineoplastic Agents, Hormonal
|
Academic Article
|
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.
|
Academic Article
|
Reply to W. Read.
|
Academic Article
|
Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
|
Academic Article
|
Toxicity and costs of toxicity associated with new cancer drugs: international implications.
|
Academic Article
|
Regulatory and clinical considerations for biosimilar oncology drugs.
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
|
Academic Article
|
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer.
|
Academic Article
|
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
|
Academic Article
|
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
|
Academic Article
|
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists.
|
Academic Article
|
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
|
Academic Article
|
Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer.
|
Academic Article
|
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
|
Academic Article
|
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.
|
Academic Article
|
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
|
Academic Article
|
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
|
Academic Article
|
Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paid.
|
Academic Article
|
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.
|
Academic Article
|
When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
|
Academic Article
|
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
|
Academic Article
|
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
|
Academic Article
|
Myeloid growth factors. Clinical practice guidelines in oncology.
|
Academic Article
|
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
|
Academic Article
|
Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.
|
Academic Article
|
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.
|
Academic Article
|
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
|
Academic Article
|
Dermatologic challenges in cancer patients and survivors.
|
Academic Article
|
Cancer- and chemotherapy-induced anemia.
|
Academic Article
|
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
|
Academic Article
|
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
|
Academic Article
|
Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer.
|
Academic Article
|
Myeloid growth factors.
|
Academic Article
|
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
|
Academic Article
|
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
|
Academic Article
|
Reassessments of ESAs for cancer treatment in the US and Europe.
|
Academic Article
|
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.
|
Academic Article
|
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
|
Academic Article
|
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).
|
Academic Article
|
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
|
Academic Article
|
The utility of prostate-specific antigen in the management of advanced prostate cancer.
|
Academic Article
|
Geography: an increasingly important variable in prostate cancer clinical trials.
|
Academic Article
|
Japanese regulatory authority's perspective on biosimilars - authors' reply.
|
Academic Article
|
Screening for viral hepatitis prior to rituximab chemotherapy.
|
Academic Article
|
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
|
Academic Article
|
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
|
Academic Article
|
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry.
|
Academic Article
|
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
|
Academic Article
|
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
|
Academic Article
|
Generic oncology drugs: are they all safe?
|
Academic Article
|
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
|
Academic Article
|
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
|
Academic Article
|
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
|
Academic Article
|
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
|
Academic Article
|
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
|
Academic Article
|
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.
|
Academic Article
|
End of an era for erythropoiesis-stimulating agents in oncology.
|
Academic Article
|
Pharmacoeconomics of amifostine in ovarian cancer.
|
Academic Article
|
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.
|
Academic Article
|
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials.
|
Academic Article
|
Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
|
Academic Article
|
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
|
Academic Article
|
Maximal androgen blockade for advanced prostate cancer.
|
Academic Article
|
Comparative study of the clinical efficacy of two dosing regimens of flutamide.
|
Academic Article
|
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
|
Academic Article
|
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
|
Academic Article
|
Cost-effectiveness considerations in the treatment of essential thrombocythemia.
|
Academic Article
|
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.
|
Academic Article
|
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
|
Academic Article
|
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
|
Academic Article
|
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
|
Concept
|
Antineoplastic Agents, Immunological
|
Academic Article
|
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
|
Academic Article
|
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions.
|
Academic Article
|
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias.
|